Skip to Content

Clinical Trials Detail

NSABP B-43: A Phase III Clinical Trial Comparing Trastumumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in Situ Resected by Lumpectomy

Objective
This is a clinical trial of Trastuzumab added to breast radiation therapy. Trastuzumab is an investigational treatment.
IRB Protocol Number
08-1266
Principal Investigator(s)
NICOLE KOUNALAKIS

Cancer Trials

  • Breast Cancer
Sponsor(s)
NSABP
Contact
BRITTANY HICKS at 720-848-0657
or BRITTANY.HICKS@UCDENVER.EDU
Eligibility and Other Participant Information
What To Expect : A screening period to determine eligibility. A treatment period that can last up to 3-6 weeks. A follow up period will consist of clinic visits. // Eligibility criteria : includes but is not limited to 18 years or older

Location

  • Shaw Regional Cancer Center (Vail)
  • ST. MARYS HOSPITAL - G.J.
  • Valley View Hospital